(HealthDay News) — For patients who undergo prostatectomy for prostate cancer, hypofractionated postoperative prostate bed radiotherapy (HYPORT) is similar to conventionally fractionated postoperative radiotherapy (COPORT) with regard to late genitourinary (GU) or gastrointestinal (GI) toxicity, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Oct. 24 to 27 in Chicago.
Mark K. Buyyounouski, MD, from the Stanford University School of Medicine in California, and colleagues randomly assigned 296 patients with prostate cancer to HYPORT (62.5 Gy to prostate bed in 25 fractions of 2.5 Gy; 144 patients) or COPORT (66.6 Gy in 37 fractions of 1.8 Gy; 152 patients). The co-primary end points were based on change scores from the GU and GI domains of the Expanded Prostate Cancer Index Composite score.
The researchers found that the differences in HYPORT and COPORT mean GU change scores were neither clinically significant nor statistically significant at the end of RT and remained so at 6 and 12 months. At the end of RT, the differences in mean GI change scores for HYPORT and COPORT were clinically significant and statistically significant, but these differences were resolved at both 6 and 12 months. The differences in 24-month mean GU and GI change scores for HYPORT and COPORT were neither clinically nor statistically significant.
“Delivering postprostatectomy radiation therapy with fewer treatments is a win when it comes to reducing the burden of prostate cancer on society,” Buyyounouski said in a statement.
Several authors disclosed financial ties to the pharmaceutical and publishing industries.